

Laura Moser

Postdoctoral Scholar, Pathology

Bio

STANFORD ADVISORS

- Ansuman Satpathy, Postdoctoral Faculty Sponsor

Research & Scholarship

LAB AFFILIATIONS

- Ansuman Satpathy (6/3/2024)
- Ansuman Satpathy (6/3/2024)
- Ansuman Satpathy (6/3/2024)

Publications

PUBLICATIONS

- **Universal T cell therapy screening library in preclinical models of CAR T cell therapy**
Eapen, A., Wu, L., Moser, L., Quach, B., Gamal, W., Rodrigues, K., Tsui, K. C., Good, Z., Roth, T.
AMER ASSOC CANCER RESEARCH.2026
- **A unified genetic perturbation language for human cellular programming.** *bioRxiv : the preprint server for biology*
Hartman, A., Takacs-Nagy, O., Kernick, C., Theberath, N. E., Lu, J., Wu, L., Mantilla, M., Mitra, S., McClellan, A., Johnson, N., Mohamad, L., Castillo-Colin, L., Hoque, et al
2025
- **Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM BLOOD ADVANCES**
Kalwak, K., Moser, L. M., Poetschger, U., Bader, P., Kleinschmidt, K., Meisel, R., Dalle, J., Yesilipek, A., Balduzzi, A., Krivan, G., Goussetis, E., Staciuk, R., Sedlacek, et al
2025; 9 (4): 741-751
- **CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in Erbb2+ rhabdomyosarcoma.** *Frontiers in immunology*
Moser, L. M., Heim, C., Koschade, S. E., Wendel, P., Bozkurt, S., Harenkamp, S., Kreyenberg, H., Merker, M., Münch, C., Gradhand, E., Vogler, M., Ullrich, E., Bönig, et al
2025; 16: 1485817
- **Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.** *Blood advances*
Bader, P., Pötschger, U., Dalle, J. H., Moser, L. M., Balduzzi, A., Ansari, M., Buechner, J., Güngör, T., Ifversen, M., Krivan, G., Pichler, H., Renard, M., Staciuk, et al
2024; 8 (2): 416-428
- **Challenges in the treatment of pediatric acute lymphoblastic leukemia: insights from the pediatric real world CAR consortium regarding nonresponse and relapse post tisagenlecleucel.** *Translational pediatrics*
Bader, P., Moser, L. M.
2023; 12 (12): 2095-2098

- **ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.** *Frontiers in immunology*
Heim, C., Moser, L. M., Kreyenberg, H., Bonig, H. B., Tonn, T., Wels, W. S., Gradhand, E., Ullrich, E., Meister, M. T., Koerkamp, M. G., Holstege, F. C., Drost, J., Klusmann, et al
2023; 14: 1228894
- **Bone Marrow Assessment in Liver Cirrhosis Patients with Otherwise Unexplained Peripheral Blood Cytopenia.** *Journal of clinical medicine*
Koschade, S. E., Moser, L. M., Sokolovskiy, A., Michael, F. A., Serve, H., Brandts, C. H., Finkelmeier, F., Zeuzem, S., Trebicka, J., Ferstl, P., Ballo, O.
2023; 12 (13)
- **Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.** *British journal of haematology*
Jarisch, A., Salzmann-Manrique, E., Soerensen, J., Sach, G., Rettinger, E., Willasch, A., Bakhtiar, S., Klarmann, D., Bräuning, S., Moser, L., Fekadu, J., Hutter, M., Klingebiel, et al
2023; 201 (6): 1159-1168
- **Treatment of inborn errors of immunity patients with inflammatory bowel disease phenotype by allogeneic stem cell transplantation.** *British journal of haematology*
Moser, L. M., Fekadu, J., Willasch, A., Rettinger, E., Sørensen, J., Jarisch, A., Kirwil, M., Lieb, A., Holzinger, D., Calaminus, G., Bader, P., Bakhtiar, S.
2023; 200 (5): 595-607
- **Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia.** *Leukemia*
Koschade, S. E., Klann, K., Shaid, S., Vick, B., Stratmann, J. A., Thölken, M., Meyer, L. M., Nguyen, T. D., Campe, J., Moser, L. M., Hock, S., Baker, F., Meyer, et al
2022; 36 (10): 2396-2407
- **Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.** *Cancers*
Gossel, L. D., Heim, C., Pfeffermann, L. M., Moser, L. M., Bönig, H. B., Klingebiel, T. E., Bader, P., Wels, W. S., Merker, M., Rettinger, E.
2021; 13 (6)
- **ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.** *Frontiers in immunology*
Merker, M., Wagner, J., Kreyenberg, H., Heim, C., Moser, L. M., Wels, W. S., Bonig, H., Ivics, Z., Ullrich, E., Klingebiel, T., Bader, P., Rettinger, E.
2020; 11: 581468